跳至主要内容
临床试验/TCTR20200116007
TCTR20200116007Unknown4 期

Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer patient, a randomized controlled trial

ational Science and Technology Development Agency0 个研究点目标入组 396 人开始时间: 2020年1月16日最近更新:
适应症

试验速览

阶段
4 期
发起方
入组人数
396

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 N/A (No limit)(—)
性别
Female

入选标准

  • 1)Female patient age > 18 years
  • 2)Diagnosis with breast cancer and planned to receive doxorubicin
  • 3)Given informed consent

排除标准

  • 1Metastatic breast cancer at diagnosis (except lymph node and bone metastasis)
  • 2Other malignancies
  • 3Prior history of chemotherapy or chest wall radiation
  • 4Prior cardiovascular disease with LVEF < 53% or severe valvular heart disease
  • 5CrCl < 30 ml/min as measured by Cockcroft-Gault Equation
  • 6Patients with baseline EKG show corrected QT interval > 500 msec
  • 7Patients currently receiving metformin or donepezil
  • 8Allergy or contraindication to metformin or donepezil
  • 9Life expectancy < 1 year
  • 10Pregnancy and lactating

研究者

发起方
ational Science and Technology Development Agency

相似试验